Treatment of tuberculosis in HIV-infected patients: We need to know more

被引：2

作者：

Perlman, David C. ^{[1
]}

Leung, Chi Chiu

Yew, Wing Wai

机构：

[1] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA

[2] Ctr Hlth Protect, Dept Hlth, TB & Chest Serv, Hong Kong, Hong Kong, Peoples R China

[3] Grantham Hosp, Hong Kong, Hong Kong, Peoples R China

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2007年 / 175卷 / 11期

关键词：

D O I：

10.1164/rccm.200702-248ED

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：1102 / 1103

页数：2

共 17 条

[1]

[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603

[2] A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment [J].

Bock, NN ;

Sterling, TR ;

Hamilton, CD ;

Pachucki, C ;

Wang, YC ;

Conwell, DS ;

Mosher, A ;

Samuels, M ;

Vernon, A .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (11) :1526-1530

[3] Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis [J].

Burman, W ;

Benator, D ;

Vernon, A ;

Khan, A ;

Jones, B ;

Silva, C ;

Lahart, C ;

Weis, S ;

King, B ;

Mangura, B ;

Weiner, M ;

El-Sadr, W .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (03) :350-356

[4] A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: Differences in study outcomes [J].

El-Sadr, WM ;

Perlman, DC ;

Denning, E ;

Matts, JP ;

Cohn, DL .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (04) :623-632

[5] Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa [J].

Gandhi, Neel R. ;

Moll, Anthony ;

Sturm, A. Willem ;

Pawinski, Robert ;

Govender, Thiloshini ;

Lalloo, Umesh ;

Zeller, Kimberly ;

Andrews, Jason ;

Friedland, Gerald .

LANCET, 2006, 368 (9547) :1575-1580

[6] Lack of weight gain and relapse risk in a large Tuberculosis Treatment Trial [J].

Khan, Awal ;

Sterling, Timothy R. ;

Reves, Randall ;

Vernon, Andrew ;

Horsburgh, C. Robert .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (03) :344-348

[7] Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000 [J].

Li, JH ;

Munsiff, SS ;

Driver, CR ;

Sackoff, J .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) :83-91

[8] Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy [J].

Manosuthi, Weerawat ;

Chottanapand, Suthat ;

Thongyen, Supeda ;

Chaovavanich, Achara ;

Sungkanuparph, Somnuek .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :42-46

[9] Treatment outcomes of patients with HIV and tuberculosis [J].

Nahid, Payam ;

Gonzalez, Leah C. ;

Rudoy, Irina ;

de Long, Bouke C. ;

Unger, Alon ;

Kawamura, L. Masae ;

Osmond, Dennis H. ;

Hopewell, Philip C. ;

Daley, Charles L. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (11) :1199-1206

[10] The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis [J].

Perlman, DC ;

Segal, Y ;

Rosenkranz, S ;

Rainey, PM ;

Remmel, RP ;

Salomon, N ;

Hafner, R ;

Peloquin, CA .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (11) :1638-1647

← 1 2 →